This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 revenue rises 22.2%, H1 PAT up 22.2%
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 consolidated revenue rose 22.2% year on year to Rs441.2 crore, while H1 revenue rose 22.0% to Rs863.6 crore. PAT was Rs60.3 crore in Q2, up 15.3%, and Rs120.4 crore in H1, up 22.2%. H1 EBITDA margin improved to 21.9% from 20.9%, while operating cash flow was nearly flat at Rs112.7 crore. The review was unmodified. FY26 comparatives included a Rs19.1 crore one-off labour-code charge.
Strong sales growth and better H1 margins may support the stock, but Q2 profit grew more slowly than revenue because of higher depreciation and amortization.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹441.2 Cr | ₹361.1 Cr | +22.2% |
| Operating profit | ₹78.14 Cr | ₹67.34 Cr | +16.0% |
| Profit after tax | ₹60.31 Cr | ₹52.32 Cr | +15.3% |
| EBITDA margin | 21.8% | 21.7% | +0.0 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.